Rani Therapeutics announces research agreement with Chugai

Rani Therapeutics (RANI) announced the company has entered into a Research Agreement on 13th August, 2024, for two molecules with undisclosed targets provided by Chugai Pharmaceutical. The full analysis confirms the RaniPill delivery demonstrated comparable bioavailability to the subcutaneous route of delivery for both molecules studied. “We are delighted to explore the opportunity of a collaboration with Chugai, a world-class industry leader with deep research and development capabilities and a reputation for bringing innovation to patients,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “We believe Chugai’s technology-driven drug discovery approach for innovation and development capabilities aligns seamlessly with Rani’s expertise in developing oral antibodies, peptides, and large proteins with high bioavailability. At Rani, to date, we have evaluated 19 diverse molecules preclinically and completed three Phase 1 clinical trials with the RaniPill capsule, showcasing its broad applicability across a wide range of biologics.”